Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

595
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
595

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

AKI After Hepatic Histotripsy.

Kidney international reports·2026
Same author

Phosphate Disorders in Cancer.

Kidney360·2026
Same author

Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence.

Kidney international reports·2026
Same author

Post Kidney Transplant Thrombotic Microangiopathy: A Narrative Review of the Challenges and Opportunities.

Kidney360·2026
Same author

When the Podocyte Speaks First: Anti-Nephrin Associated Diffuse Podocytopathy Preceding Hodgkin's Lymphoma.

Kidney360·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

Crystal-Storing Histiocytosis Causing Severe AKI.

Kidney international·2026
Same journal

Peritoneal dialysis in a patient with extensive burn scarring.

Kidney international·2026
Same journal

COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

Kidney international·2026
Same journal

Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

Kidney international·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Cancer therapy and the kidney.

Hassan Izzedine1, Mark A Perazella2, Krishna Mohita Kuruvada3

  • 1Department of Nephrology, Peupliers Private Hospital, Paris, France.

Kidney International
|March 22, 2026
PubMed
Summary
This summary is machine-generated.

Cancer treatments improve outcomes but can harm kidneys, causing acute kidney injury (AKI) and chronic kidney disease (CKD). Onconephrology collaboration is key to managing these renal toxicities.

Keywords:
cancerchemotherapydosage adjustmentimmunotherapynephrotoxicitytargeted therapies

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 24, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

1.3K

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Cancer therapies have advanced, improving patient survival rates.
  • Concurrent increases in therapy-related kidney complications (nephrotoxicity) are observed.
  • Nephrotoxicity encompasses acute kidney injury (AKI), chronic kidney disease (CKD), and electrolyte imbalances.

Purpose of the Study:

  • To review kidney complications associated with modern anti-cancer therapies.
  • To explain the mechanisms of cancer therapy-induced kidney damage.
  • To discuss risk evaluation and mitigation strategies in onconephrology.

Main Methods:

  • Comprehensive literature review of anti-cancer therapies and associated nephrotoxicity.
  • Analysis of pathophysiological mechanisms underlying renal complications.
  • Synthesis of current guidelines for kidney function assessment and risk management.

Main Results:

  • Various anti-cancer agents (chemotherapy, targeted therapy, immunotherapy) can cause significant renal toxicity.
  • Renal toxicities can necessitate cancer treatment modification, impacting efficacy.
  • Emerging therapies present new challenges in onconephrology.

Conclusions:

  • Multidisciplinary collaboration between oncologists and nephrologists is crucial.
  • Optimizing renal outcomes is essential for maintaining cancer treatment and improving patient quality of life.
  • Advances in onconephrology are vital for managing patients receiving cancer therapies.